Skip to search formSkip to main contentSkip to account menu

GLPG0634

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

PyridinesTriazoles

Narrower (1)

filgotinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OP0161 The JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis
Background Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease characterized by the association of… 
2016
2016
THU0173 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study
Background Filgotinib (GLPG0634) is a novel oral, selective JAK1 inhibitor that was evaluated in a 24-week phase 2B study as… 
2016
2016
THU0167 The Effect of Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2b Dose Ranging Studies
Background Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that showed rapid and sustained… 
2016
2016
812c Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis
2015
2015
Comment on: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
With the recent approval of rofacitinib for the management of moderate to severe rheumatoid arthritis, the inhibition of Janus… 
2014
2014
THU0123 Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach
Background GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Less-selective JAK inhibitors have shown… 
2014
2014
P072 GLPG0634, the first selective JAK1 inhibitor, shows strong activity in the mouse DSS-colitis model
2013
2013
THU0229 Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase II a Dose Ranging, Multi-Center Trial
Background GLPG0634 is an orally-available, selective inhibitor of Janus kinase 1 (JAK1). JAKs are critical in signaling for… 
2013
2013
THU0116 Biological Effects of the JAK1 Selective Inhibitor GLPG0634 on Inflammation Markers in Arthritic Mice
Background Non-selective Janus kinase (JAK) inhibitors have shown long-term efficacy in treating rheumatoid arthritis (RA… 
2012
2012
Biotech equities heat up in 1Q12
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)